Back to search
REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS
Clinical trial pipeline · Data from ClinicalTrials.gov
See which REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS trials you may qualify forThe main objective is to assess the safety and tolerability of inebilizumab in adult participants with active and refractory systemic lupus erythematosus (SLE)…
A Phase 1 study of HBI0101 BCMA-CART in B-Cell Mediated Autoimmune Rheumatic Diseases. The goal of the study is evaluation of safety and identification of the m…
The purpose of this study is to establish the tolerability, preliminary efficacy, and pharmacokinetics of CC-97540 in participants with severe, refractory autoi…
A single arm, open-label pilot study is designed to determine the safety and effectiveness of anti-CD19/BCMA-UCAR-T cells in patients with autoimmune diseases.…
The purpose of this study is to determine the safety, tolerability, optimal dose, and preliminary efficacy of BMS-986515, a healthy donor (HD) allogeneic CD19-t…
To investigate biomarkers to identify pediatric SR-SLE patients by non-invasive echocardiographic techniques.
The primary objective of this trial is to evaluate the efficacy and safety of FT819, comprised of allogeneic T cells that express a CD19-targeted CAR, following…
In this study, researchers will learn more about a study drug called BIIB059 (litifilimab) in participants with cutaneous lupus erythematosus (CLE). The study w…